ANAB Projected Dividend Yield
AnaptysBio Inc ( NASDAQ : ANAB )AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. Co. is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. Co.'s preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. 21 YEAR PERFORMANCE RESULTS |
ANAB Dividend History Detail ANAB Dividend News ANAB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |